Glenmark Pharmaceuticals Ltd share price logo

Glenmark Pharmaceuticals Ltd (GLENMARK)

₹1019.551.42%

bell
Get free price alerts. Set up your Free investment account to get Live Prices. >
Overview
Fundamentals
Q3 '23 Results
Technicals
News and Events

Glenmark Pharmaceuticals Ltd share Performance

  • ₹999.8
    ₹1,021.5
    ₹1019.55
    downward going graph

    1.94%

    Low

    Day's Volatility:2.13%

    High

    0.19%

    downward going graph
  • ₹581
    ₹1,098
    ₹1019.55
    downward going graph

    43.01%

    Low

    52 Weeks Volatility:50.71%

    High

    7.69%

    downward going graph
1 Month Return-3.5 %
3 Month Return+ 16.55 %
1 Year Return+ 65.11 %
Previous Close₹1,005.30
Open₹1,010.00
Volume3.43L
Upper Circuit-
Lower Circuit-
Market Cap₹28,368.38Cr

Analyst Rating

based on 14 analysts

BUY
42.86%
Buy
35.71%
Hold
21.43%
Sell

Based on 14 analysts offering long term price targets for Glenmark Pharmaceuticals Ltd. An average target of ₹962.79

Source: S&P Global Market Intelligence

Company Information

Glenmark Pharmaceuticals Ltd is an Indian pharmaceuticals company listed on the National Stock Exchange and Bombay Stock Exchange. Established in 1977, the company manufactures and distributes branded and generic formulations, active pharmaceutical ingredients (API’s) and biosimilars. It has 18 manufacturing facilities in India, 7 in the U.S., 1 in Brazil and 1 in Mexico that span across the world catering to global requirements. Glenmark has taken several steps towards achieving a healthy presence in the global markets. In addition to its product portfolio, Glenmark’s aggressive acquisition strategy and product launch activities have helped expand its market reach. The company has been awarded numerous accolades over the years, including consecutive years of being ranked amongst the top 1000 world pharmaceutical companies. It continues to be a frontrunner in providing quality and affordable healthcare solutions in India and abroad.

Share Price: ₹1019.55 per share as on 17 May, 2024 04:01 PM
Market Capitalisation: ₹28,368.38Cr as of today
Revenue: ₹2,460.29Cr as on December 2023 (Q4 23)
Net Profit: ₹-330.82Cr as on December 2023 (Q4 23)
Listing date: 10 Feb, 2000
Chairperson Name: Glenn Saldanha
OrganisationGlenmark Pharmaceuticals Ltd
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Glenmark Pharmaceuticals Ltd

  • Glenmark Pharma Receives Final Approval for Ophthalmic Solution - 17 May, 2024

    Glenmark Pharmaceuticals has received final approval from the USFDA for its Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%. The product is deemed bioequivalent and therapeutically equivalent to AbbVie's Combigan Ophthalmic Solution, 0.2%/0.5%, with annual sales of approximately $290 million.

  • Glenmark Pharmaceuticals Potentially Overvalued - 08 May, 2024

    Based on a 2 Stage Free Cash Flow to Equity analysis, Glenmark Pharmaceuticals is estimated to be 34% overvalued with a fair value of ₹759. The company appears potentially overvalued at the current share price of ₹1.0k.

  • Glenmark Pharma Receives USFDA Approval for Edaravone Injection - 07 May, 2024

    Glenmark Pharmaceuticals has received USFDA approval for its Edaravone injection, which is therapeutically and bioequivalent to the reference-listed drug Radicava injection. The company plans to launch the product via its marketing partner during fiscal year 2025. Gland Pharma reported about USD 19 million in sales in the US for the year ending January 2024.

  • Glenmark Recalls Blood Pressure Drug in US Market - 05 May, 2024

    Glenmark Pharmaceuticals has recalled 3,264 bottles of Diltiazem Hydrochloride extended-release capsules from the US market due to failed dissolution specifications. The drug is used to treat high blood pressure.

  • Glenmark Pharma Receives FDA Approval for Acetaminophen and Ibuprofen Tablets - 03 May, 2024

    Glenmark Pharmaceuticals has received final approval from the US FDA for its Acetaminophen and Ibuprofen Tablets, which are bioequivalent to Advil Dual Action with Acetaminophen Tablets. The market achieved annual sales of approximately $84.1 million.

  • Glenmark Pharma Gets USFDA Approval for New Drug - 29 Apr, 2024

    Glenmark Pharmaceuticals has received final approval from the US FDA for its Acetaminophen and Ibuprofen tablets, which will be distributed in the US by Glenmark Therapeutics Inc. The new drug is used to relieve minor pains such as headaches, backaches, toothaches, menstrual cramps, muscle aches or arthritis pain. Shares of Glenmark Pharma gained more than 1% on the news.

Fundamentals of Glenmark Pharmaceuticals Ltd

Insights on Glenmark Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, GLENMARK stock has moved up by 16.6%

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 8.59% to 10.55% in Mar 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Zydus Lifesciences Ltd has given 94.5% return, outperforming this stock by 29.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 123.6% return, outperforming this stock by 57.2%

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 23.71% to 21.38% in Mar 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 18.69% to 18.58% in Mar 2024 quarter

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 46.65% to 46.64% in Mar 2024 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 149.93 Cr → -351.37 Cr (in ₹), with an average decrease of 241.7% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 3.32K Cr → 2.67K Cr (in ₹), with an average decrease of 19.7% per quarter

Glenmark Pharmaceuticals Ltd Valuation

Glenmark Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (-275.05x)

December 28, 2023

Today (-39.86x)

May 16, 2024

Industry (61.87x)

May 16, 2024

Highest (95.94x)

September 14, 2023

LowHigh

Mutual Fund Holdings

Funds Holdings
HDFC Mid-Cap Opportunities Fund -Direct Plan - Growth OptionHDFC Mid-Cap Opportunities Fund -Direct Plan - Growth Option1%
Aditya Birla Sun Life Flexi Cap Fund Direct Plan GrowthAditya Birla Sun Life Flexi Cap Fund Direct Plan Growth1.34%
SBI Arbitrage Opportunities Fund Direct GrowthSBI Arbitrage Opportunities Fund Direct Growth0.48%
Kotak Equity Arbitrage Fund Direct GrowthKotak Equity Arbitrage Fund Direct Growth0.3%
Aditya Birla Sun Life Mid Cap Fund Direct Plan GrowthAditya Birla Sun Life Mid Cap Fund Direct Plan Growth2.26%

Shareholding Pattern

InvestorsHoldings %Prev. 1 periods3M change
Promoter Holdings
46.64%
0.00
Foreign Institutions
21.38%
0.00
Mutual Funds
10.55%
0.00
Retail Investors
18.58%
0.00
Others
2.85%
0.00

Technicals of Glenmark Pharmaceuticals Ltd share

News & Events of Glenmark Pharmaceuticals Ltd

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Glenmark Pharmaceuticals Ltd shares.

Glenmark Pharmaceuticals Ltd (GLENMARK) share price today is ₹1019.55

Glenmark Pharmaceuticals Ltd is listed on NSE

Glenmark Pharmaceuticals Ltd is listed on BSE

  • Today’s highest price of Glenmark Pharmaceuticals Ltd is ₹1021.5.
  • Today’s lowest price of Glenmark Pharmaceuticals Ltd is ₹999.8.

PE Ratio of Glenmark Pharmaceuticals Ltd is -39.86

PE ratio = Glenmark Pharmaceuticals Ltd Market price per share / Glenmark Pharmaceuticals Ltd Earnings per share

Today’s traded volume of Glenmark Pharmaceuticals Ltd(GLENMARK) is 3.43L.

Today’s market capitalisation of Glenmark Pharmaceuticals Ltd(GLENMARK) is ₹28368.38Cr.

Glenmark Pharmaceuticals Ltd(GLENMARKPrice
52 Week High
₹1098
52 Week Low
₹581

Glenmark Pharmaceuticals Ltd(GLENMARK) share price is ₹1019.55. It is down -7.14% from its 52 Week High price of ₹1098

Glenmark Pharmaceuticals Ltd(GLENMARK) share price is ₹1019.55. It is up 75.48% from its 52 Week Low price of ₹581

Glenmark Pharmaceuticals Ltd(GLENMARKReturns
1 Day Returns
14.25%
1 Month Returns
-3.5%
3 Month Returns
16.55%
1 Year Returns
65.11%